Literature DB >> 21991096

A comparative study of burns treated with topical heparin and without heparin.

T S Venakatachalapathy1, S Mohan Kumar, M J Saliba.   

Abstract

Following reports of heparin use in burn treatment, an ethics-committee-approved prospective randomized study with controls compared results obtained using traditional usual burn treatment without heparin with results in similar patients similarly treated with heparin added topically. The subjects were 100 consecutive burn patients (age, 15-35 yr) with second-degree superficial and deep burns of 5-45% TBSA size. Two largely similar cohort groups, i.e. a control group (C) and a heparin group (H) with 50 subjects per group, were randomly treated, the main difference between the groups being that 13 C patients had burns of 35-45% extent vs. only one such patient in H (p < 0.01). The 50 C patients received traditional routine treatment, including topical antimicrobial cream, debridement, and, when needed, skin grafts in the early post-burn period. The 50 H patients, without topical cream, were additionally treated, starting on day 1 post-burn, with 200 IU/ml sodium aqueous heparin solution USP (heparin) dripped on the burn surfaces and inserted into the blisters 2-4 times a day for 1-2 days, and then only on burn surfaces for a total of 5-7 days, prior to skin grafting, when needed. Thereafter, C and H treatment was similar. It was found that the H patients complained of less pain and received less pain medicine than the C patients. H needed fewer dressings and oral antibiotics than C. Significantly less intravenous fluid was infused in H: 33.5 litres in 39 H patients vs. 65 litres in 41 C patients, i.e. nearly 50% less (p < 0.04). The 50 H patients had four skin graftings (8%), while the 50 C patients had 10 (20%). Five 5 C patients died (mortality, 10%). No H patients died. The number of days in hospital for H vs. C was significantly less (overall, p < 0.0001): 58% of H were discharged within 10 days vs. 6% of C; 82% of H were out in 20 days vs. 14% of C; 98% of H vs. 44% of C were out in 30 days; and while 100% of H were discharged by day 40, 56% of C required up to another 10 days. The burns in H patients healed on average in 15 days (maximum period 37 days) vs. an average of 25 days (maximum > 48 days) in C (p < 0.0006). Procedures and costs in H were much reduced compared with C. Photographs of the differences between H and C are presented for the sake of comparison. It is concluded that heparin applied topically for 5-7 days improved burn treatment: it reduced pain, pain medicine, dressings, and use of antibiotics; it significantly reduced IV fluids (p < 0.04), days in hospital (p < 0.0001), and healing time (p < 0.0006); and it reduced skin grafts, mortality, and costs.

Entities:  

Keywords:  BURNS; COMPARATIVE; HEPARIN; STUDY; TOPICAL; TREATED; WITH; WITHOUT

Year:  2007        PMID: 21991096      PMCID: PMC3188086     

Source DB:  PubMed          Journal:  Ann Burns Fire Disasters        ISSN: 1592-9558


  11 in total

1.  Application of heparin in the local treatment of burns.

Authors:  K Troshev; R Dimitrov
Journal:  Acta Chir Plast       Date:  2001

Review 2.  The effects and uses of heparin in the care of burns that improves treatment and enhances the quality of life.

Authors:  M J Saliba
Journal:  Acta Chir Plast       Date:  1997

3.  Large burns in humans. Treatment with heparin.

Authors:  M J Saliba; W C Dempsey; J L Kruggel
Journal:  JAMA       Date:  1973-07-16       Impact factor: 56.272

4.  Production of heparin-binding epidermal growth factor-like growth factor (HB-EGF) at sites of thermal injury in pediatric patients.

Authors:  D W McCarthy; M T Downing; D R Brigstock; M H Luquette; K D Brown; M S Abad; G E Besner
Journal:  J Invest Dermatol       Date:  1996-01       Impact factor: 8.551

5.  Reduction of bacterial translocation and intestinal structural alterations by heparin in a murine burn injury model.

Authors:  R L Zapata-Sirvent; J F Hansbrough; G E Greenleaf; L S Grayson; P Wolf
Journal:  J Trauma       Date:  1994-01

6.  Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain.

Authors:  T Maciag; T Mehlman; R Friesel; A B Schreiber
Journal:  Science       Date:  1984-08-31       Impact factor: 47.728

Review 7.  Control of angiogenesis by heparin and other sulfated polysaccharides.

Authors:  J Folkman; Y Shing
Journal:  Adv Exp Med Biol       Date:  1992       Impact factor: 2.622

8.  Studies on vascular smooth muscle cells and dermal fibroblasts in collagen matrices. Effects of heparin.

Authors:  H P Ehrlich; T R Griswold; J B Rajaratnam
Journal:  Exp Cell Res       Date:  1986-05       Impact factor: 3.905

9.  The effect of heparin on cell proliferation and type-I collagen synthesis by adult human dermal fibroblasts.

Authors:  A V Ferrao; R M Mason
Journal:  Biochim Biophys Acta       Date:  1993-01-22

10.  Mast cell heparin stimulates migration of capillary endothelial cells in vitro.

Authors:  R G Azizkhan; J C Azizkhan; B R Zetter; J Folkman
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  3 in total

1.  Letter to the editors.

Authors: 
Journal:  Ann Burns Fire Disasters       Date:  2008-03-31

2.  A comparative study of paediatric thermal burns treated with topical heparin and without heparin.

Authors:  T S Venkatachalapathy
Journal:  Indian J Surg       Date:  2012-10-05       Impact factor: 0.656

3.  Randomized, double-blind, placebo-controlled, interventional phase IV investigation to assess the efficacy and safety of r-hirudin gel (1120I.U) in patients with hematomas.

Authors:  Hani El-Mowafi; Ahmed El Araby; Yasser Kandil; Ahmed Zaghloul
Journal:  Res Pract Thromb Haemost       Date:  2017-11-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.